Nanomedicine News

RSS

New Set of Building Blocks Based on Nanoparticles and DNA

Northwestern University's Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has developed a completely new set of building blocks that is based on nanoparticles and DNA. Using these tools, scientists will be able to build -- from the bottom up, just as nature does -- new and useful structures.

18 Feb 2013

Mussel-Inspired Polymer Coating Helps Gold Nanorods Target Cancer Cells

When it comes to sticking power under wet conditions, marine mussels are hard to beat. They can adhere to virtually all inorganic and organic surfaces, sustaining their tenacious bonds in saltwater, including turbulent tidal environments.

18 Feb 2013

Northwestern University Researcher Develops Spherical Nucleic Acids Using Nanotechnology

Northwestern University's Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has invented and developed a powerful material that could revolutionize biomedicine: spherical nucleic acids (SNAs).

16 Feb 2013

Researcher Works on Delivering Chemotherapeutics Using Nano-Vehicles for Cancer Treatment

Jeremy L. Steinbacher, PhD, is among a new generation of scientists trying to improve their aim and approach to killing cancer cells. The Canisius College professor of chemistry/biochemistry is working to develop biomedical agents that more accurately target and attack tumors.

15 Feb 2013

PI UK Launches Custom Turnkey System Design and Manufacture Service - PI Custom Motion Systems

The UK office of mechanical positioning technology manufacturer Physik Instrumente (PI) today announces the launch of PI Custom Motion Systems - a dedicated application and product customisation service to meet growing local demand for complete, bespoke, mechanical positioning systems that offer the highest possible accuracy and precision.

From Physik Instrumente (PI) GmbH & Co KG 13 Feb 2013

Tekmira Reports Key Milestones in Product Development

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today its key product development, corporate, and partner milestones for 2013.

13 Feb 2013

NanoViricides to Participate in 15th Annual BIO CEO and Investor Conference

NanoViricides, Inc. (the "Company") announced today that its President, Dr. Anil Diwan, will present an overview of the company at the 15th Annual BIO CEO and Investor Conference. The Conference is being held at the Waldorf-Astoria Hotel in New York City.

From NanoViricides, Inc 13 Feb 2013

RNA-Carrying Nanoliposomes Effectively Target Ovarian Cancer Cells

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

Liposomal Nanoparticle-Delivered miR-506 Holds Promise for Ovarian Cancer Treatment

Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease.

12 Feb 2013

Novel RNAi and Lipid Nanoparticle Drug Demonstrates Significant Results in Treating Cancer

A study led by Dr Josep Tabernero, the Director of Clinical Research at the Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, shows for the first time that ribonucleic acid interference (RNAi) is effective in the treatment of cancer patients. Harnessing these molecules to silence genes involved in the development and growth of cancer cells is an important step forward in developing a new and more targeted type of cancer therapy.

12 Feb 2013